Evenity (Romosozumab) Dosing in Renal Impairment

How Romosozumab Works: Sclerostin Inhibition and Bone Formation

Romosozumab is a humanized monoclonal antibody that binds and inhibits sclerostin, a glycoprotein produced primarily by osteocytes. Sclerostin normally suppresses the Wnt signaling pathway in osteoblasts, acting as a brake on bone formation. By neutralizing sclerostin, romosozumab releases that brake.

The result is a dual-action effect on bone metabolism that no other approved osteoporosis drug replicates. Bone formation markers (P1NP) rise sharply within the first month of treatment, peaking at roughly 145% above baseline by month 1, then gradually declining over the 12-month course 1. Bone resorption markers (CTX) simultaneously decrease by approximately 30 to 40% from baseline during the same period. This combination of increased formation and decreased resorption produces rapid gains in bone mineral density (BMD). In the FRAME trial (N=7,180), romosozumab increased lumbar spine BMD by 13.3% and total hip BMD by 6.9% at 12 months compared with placebo 2.

This pharmacology matters for the renal discussion. Because romosozumab is a large monoclonal antibody (molecular weight approximately 149 kDa), it is not filtered by the glomerulus. Its clearance depends on the reticuloendothelial system and target-mediated disposition, not kidney excretion 3. That single fact is why no dose adjustment is needed across the entire spectrum of renal function.

FDA Labeling: No Dose Adjustment Required

The Evenity prescribing information is explicit. No dose modification is recommended for patients with renal impairment, including those on hemodialysis 3. The dose remains 210 mg administered as two subcutaneous injections of 105 mg each, given once monthly for 12 consecutive months.

This stands in contrast to bisphosphonates. Alendronate and risedronate are contraindicated below an eGFR of 30 to 35 mL/min/1.73 m², and zoledronic acid is contraindicated below 35 mL/min/1.73 m² 4. Denosumab, like romosozumab, requires no renal dose adjustment, but carries its own hypocalcemia burden in CKD. The absence of renal contraindications makes romosozumab and denosumab the two bone-active agents available for patients with severe kidney disease who have confirmed osteoporosis (as distinguished from renal osteodystrophy).

The FDA label does carry a specific warning: "Hypocalcemia must be corrected prior to initiating Evenity. Patients with severe renal impairment (creatinine clearance <30 mL/min) or receiving dialysis are at greater risk of hypocalcemia" 3. The label instructs clinicians to adequately supplement patients with calcium and vitamin D and to monitor serum calcium.

Pharmacokinetics Across Kidney Disease Stages

Population pharmacokinetic analyses submitted to the FDA evaluated romosozumab exposure in subjects with mild (eGFR 60 to 89), moderate (eGFR 30 to 59), and severe (eGFR <30) renal impairment. Creatinine clearance did not meaningfully alter romosozumab steady-state exposure 3.

A dedicated renal impairment study (Study 20060326) enrolled subjects across renal function categories, including patients requiring hemodialysis. Results showed that area under the curve (AUC) values were comparable across groups, with no clinically significant differences in maximum concentration (Cmax) or time to maximum concentration (Tmax) 5. Hemodialysis itself did not remove the drug, which is expected given its molecular size.

This pharmacokinetic profile confirms that kidney function does not affect how much drug reaches bone tissue. The clinical challenge in CKD is not about drug levels. It is about the metabolic environment the drug enters.

Hypocalcemia Risk: The Central Clinical Concern

In patients with normal kidney function, symptomatic hypocalcemia from romosozumab is rare. The FRAME and ARCH trials excluded patients with eGFR <30 mL/min/1.73 m², so the controlled data in advanced CKD are limited 2 6. Post-marketing surveillance and case series have filled some of that gap.

Patients with CKD stages 4 and 5 frequently have baseline disruptions in calcium, phosphate, parathyroid hormone (PTH), and vitamin D metabolism. Secondary hyperparathyroidism is nearly universal at eGFR <30. Adding a potent bone-forming agent to this environment accelerates calcium uptake into newly forming bone matrix, which can precipitously lower serum calcium.

The FDA Adverse Event Reporting System (FAERS) has captured cases of severe hypocalcemia in CKD patients receiving romosozumab, including events requiring intravenous calcium gluconate 3. While the absolute number of reported events remains small relative to total prescriptions, the severity of individual episodes is high enough to demand a structured monitoring protocol.

Pre-Treatment Calcium and Vitamin D Optimization

Before initiating romosozumab in any CKD patient, confirm:

• Serum 25-hydroxyvitamin D ≥30 ng/mL. If deficient, replete with ergocalciferol 50 to 000 IU weekly for 6 to 8 weeks, then maintain with cholecalciferol 1,000 to 2 to 000 IU daily.
• Corrected serum calcium within the normal laboratory range (8.5 to 10.5 mg/dL).
• Intact PTH measured and trending. Markedly elevated PTH (above 500 to 600 pg/mL) may indicate adynamic bone disease or severe secondary hyperparathyroidism requiring separate management before considering romosozumab.
• In dialysis patients, use the activated vitamin D analog (calcitriol or paricalcitol) and phosphate binders already part of their CKD-MBD regimen 7.

Monitoring During Treatment

For patients with eGFR <30 or on dialysis, the following monitoring schedule is appropriate:

• Serum calcium (corrected for albumin) at baseline, then within 7 to 14 days after each of the first 3 injections.
• If calcium remains stable after 3 doses, extend monitoring to monthly (pre-injection).
• Serum phosphate and intact PTH every 3 months during the 12-month course.
• 25-hydroxyvitamin D at 3 and 6 months to confirm adequacy of supplementation.

Any episode of symptomatic hypocalcemia (perioral tingling, carpopedal spasm, QTc prolongation) requires immediate treatment and reassessment before the next scheduled dose.

Distinguishing Osteoporosis From Renal Osteodystrophy in CKD

This is where clinical judgment becomes non-negotiable. CKD-MBD encompasses a spectrum of bone disorders, including osteitis fibrosa (high-turnover from hyperparathyroidism), adynamic bone disease (low-turnover), mixed uremic osteodystrophy, and osteomalacia 7. Romosozumab is FDA-approved for osteoporosis. It is not indicated for renal osteodystrophy.

The KDIGO 2017 guidelines recommend that in patients with CKD stages 3a through 5D, clinicians should assess fracture risk before prescribing osteoporosis therapies and should consider bone biopsy when the type of renal osteodystrophy would change management 7. A bone biopsy with tetracycline double-labeling remains the gold standard for distinguishing these entities, though it is rarely performed in practice.

Practically, the patients most appropriate for romosozumab in CKD are those with:

• Documented low BMD by DXA (T-score ≤ minus 2.5 at the spine, hip, or femoral neck).
• A prior fragility fracture or high FRAX probability.
• Biochemical markers suggesting that standard osteoporosis (not adynamic bone disease or severe hyperparathyroidism) is the predominant pathology.
• PTH levels that, while elevated, are not in the range suggesting severe autonomous hyperparathyroidism (generally below 800 pg/mL, though this threshold is debated).

The 2020 AACE/ACE guidelines note that romosozumab may be considered in very high fracture risk patients with CKD, with the caveat that hypocalcemia monitoring must be intensified 8.

The ARCH Trial: Efficacy Data and Renal Subgroup Observations

The ARCH trial (N=4,093) randomized postmenopausal women with osteoporosis and a prior fracture to romosozumab 210 mg monthly for 12 months followed by alendronate, versus alendronate alone 6. At 24 months, romosozumab-to-alendronate reduced new vertebral fractures by 48% relative to alendronate alone (6.2% vs. 11.9%, P<0.001). Non-vertebral fracture risk dropped by 19% (P=0.04).

The trial enrolled patients with creatinine clearance ≥30 mL/min. Pre-specified subgroup analyses by baseline renal function (eGFR 30 to 59 vs. ≥60) showed consistent fracture reduction benefit across both groups, though the trial was not individually powered for the CKD subgroup 6.

The FRAME trial (N=7,180) similarly excluded eGFR <30 and showed a 73% reduction in new vertebral fractures at 12 months with romosozumab versus placebo 2. BMD gains were consistent regardless of baseline renal function within the enrolled range.

What these trials do not tell us is whether efficacy holds in eGFR <30 or dialysis populations. No randomized controlled trial has specifically studied romosozumab in that group. The pharmacokinetic data support equivalent drug exposure, but fracture reduction in the setting of CKD-MBD pathology has not been confirmed in a controlled setting.

Cardiovascular Safety: The Boxed Warning in Context

The FDA boxed warning states that romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death, and should not be used in patients who have had an MI or stroke within the preceding year 3. This warning is relevant to the CKD population because cardiovascular disease prevalence is disproportionately high in patients with advanced kidney disease.

In the ARCH trial, adjudicated major adverse cardiovascular events (MACE) occurred in 2.5% of the romosozumab group versus 1.9% of the alendronate group during the 12-month romosozumab treatment period 6. Whether this signal reflects a true drug effect or imbalance in baseline cardiovascular risk remains debated in the literature. A meta-analysis by Lv et al. (2020) pooled data from ARCH, FRAME, and BRIDGE and found no statistically significant increase in MACE with romosozumab versus placebo (RR 1.18 to 95% CI 0.73 to 1.90) but did find a signal versus active comparator 9.

For CKD patients, the clinical calculus is straightforward: perform a cardiovascular risk assessment before prescribing. Document the absence of recent MI or stroke. In dialysis patients with known coronary artery disease or cardiomyopathy, weigh the fracture reduction benefit against the uncertain cardiovascular signal on a case-by-case basis.

Post-Romosozumab Sequencing in CKD

Romosozumab's bone-forming effect wanes after the 12-month course. BMD gains are lost rapidly without follow-on antiresorptive therapy 10. In patients with normal renal function, the standard sequence is romosozumab for 12 months followed by denosumab or a bisphosphonate.

In CKD stages 4 and 5, the sequencing options narrow. Bisphosphonates are contraindicated. Denosumab remains available regardless of eGFR, but carries its own hypocalcemia risk in CKD and requires an indefinite dosing commitment (discontinuation triggers rebound bone loss and vertebral fracture risk) 11.

The recommended approach for advanced CKD patients completing romosozumab:

• Transition to denosumab 60 mg SC every 6 months.
• Continue calcium, vitamin D, and calcitriol supplementation.
• Monitor serum calcium within 10 to 14 days of each denosumab dose.
• Do not discontinue denosumab without a clear plan for bisphosphonate bridging, which may become feasible if renal function improves (e.g., post-transplant).

Kidney Transplant Recipients: A Special Population

Post-transplant osteoporosis is common, driven by glucocorticoid use, calcineurin inhibitor effects on bone, and pre-existing CKD-MBD. Small case series have described romosozumab use in kidney transplant recipients, showing BMD improvements at the lumbar spine of 5 to 10% at 12 months without episodes of graft dysfunction 12. These data are preliminary. No randomized trial has evaluated romosozumab post-transplant.

Before prescribing in transplant recipients, verify stable graft function (ideally eGFR >30) and ensure that immunosuppressive regimens have been optimized with the lowest feasible glucocorticoid dose. Calcium monitoring protocols follow the same CKD guidance outlined above.

Practical Dosing Protocol Summary

The 210 mg dose is delivered as two separate 105 mg/1.17 mL prefilled syringes, injected subcutaneously into the abdomen, thigh, or upper arm. Both injections should be administered consecutively at the same visit. Sites should be rotated monthly.

For CKD patients, no modification to the injection technique, volume, or schedule is needed. The only additions are the pre-treatment laboratory workup, intensified calcium monitoring, and the cardiovascular risk documentation described above. Treatment duration is fixed at 12 monthly doses, with no extension beyond 12 months recommended by the FDA label 3.

Serum calcium should be checked within 14 days of dose 1 in any patient with eGFR <30 mL/min/1.73 m².